Author:
Addison Christina L.,Bouganim Nathaniel,Hilton John,Vandermeer Lisa,Dent Susan,Amir Eitan,Hopkins Sean,Kuchuk Iryna,Segal Roanne,Song Xinni,Gertler Stan,Mazzarello Sasha,Dranitsaris George,Ooi Daylily,Pond Gregory,Clemons Mark
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE (1995) A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 72(5):1289–1293
2. Kimmel DB (2007) Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86(11):1022–1033
3. Kuchuk I, Clemons M, Addison C (2012) Time to put an end to the “one size fits all” approach to bisphosphonate use in patients with metastatic breast cancer? Curr Oncol 19(5):e303–e304. doi: 10.3747/co.19.1009
4. Verma S, Kerr-Cresswell D, Dranitsaris G, Charbonneau F, Trudeau M, Yogendran G, Cesta AM, Clemons M (2004) Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists. Support Care Cancer 12(12):852–858. doi: 10.1007/s00520-004-0671-9
5. Clemons M, Enright K, Cesta A, Charbonneau F, Chow E, Warr D, Kee-Cresswell D, Chang J, Yogendran G, Trudeau M, De Angelis C, Cottrell W, Dranitsaris G (2004) Do physicians follow systemic treatment and funding policy guidelines? Can J Clin Pharmacol 11(1):e168–e178
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献